# Lorlatinib in ROS1+ NSCLC With Brain Metastasis

> **NCT07083687** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Lorlatinib 100 mg

## Key facts

- **NCT ID:** NCT07083687
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083687, "Lorlatinib in ROS1+ NSCLC With Brain Metastasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07083687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*